Immunotherapy for pancreatic cancer — science driving clinical progress
- 20 May 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 5 (6), 459-467
- https://doi.org/10.1038/nrc1630
Abstract
The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.Keywords
This publication has 85 references indexed in Scilit:
- Chronic exposure of transforming growth factor beta 1 confers a more aggressive tumor phenotype through downregulation of p21WAF1/CIP1 in conditionally immortalized pancreatic epithelial cellsSurgery, 2004
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004
- Mouse models of pancreatic cancer: The fur is finally flying!Cancer Cell, 2004
- Synergy between tumor immunotherapy and antiangiogenic therapyBlood, 2003
- The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune ResponsesAnnual Review of Immunology, 2002
- The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissuesSeminars in Cancer Biology, 1999
- MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer VaccinesImmunological Reviews, 1995
- Cellular Mucins: Targets for ImmunotherapyCritical Reviews™ in Immunology, 1994
- The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathwaysCell, 1991
- T cell antigen receptor activation pathways: The tyrosine kinase connectionCell, 1991